Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarsus Pharmaceuticals

www.tarsusrx.com

Latest From Tarsus Pharmaceuticals

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

Pfizer Opts for Access Over Exclusivity in Antibodies

For its biggest antibody deal to date, Pfizer choose Medarex, which insists on non-exclusive agreements, leaving the biotech free to work with other partners on any given target. In doing so, Pfizer reckoned that the potential for competition with respect to a particular target was outweighed by the greater access to targets which Medarex's deal model provides.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Tarsus Pharmaceuticals
  • Senior Management
  • Bobby Azamian, CEO
    Maaza Martin, Dir., Mktg.
  • Contact Info
  • Tarsus Pharmaceuticals
    Phone: (949) 409-9820
    19782 MacArthur Blvd., Ste. 285
    Irvine, CA 92612
    USA
UsernamePublicRestriction

Register